This was the stock's second consecutive day of losses.

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Turning to Wall Street, the analysts’ consensus rating for Novavax is Hold, based on one Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NVAX stock price ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and Intuitive Surgical (ISRG – Research Repor ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...